Employers Hold the Line on GLP-1 Weight Loss Drug Coverage
A new survey shows employer coverage of GLP-1 drugs for obesity has stalled at 36%, with many companies seeking workarounds to limit costs.
Employer coverage of GLP-1 medications for obesity treatment has flatlined, with a new survey revealing that just 36% of companies now cover the blockbuster drugs for both diabetes and weight loss — unchanged from 2025 and only marginally higher than the 34% recorded in 2024. The stagnation signals that despite surging demand for drugs like Ozempic and Wegovy, corporate benefits managers are pressing the brakes rather than expanding access.
The near-freeze in coverage growth comes even as GLP-1 medications have become some of the most talked-about pharmaceutical products in recent memory, praised for their effectiveness in treating obesity and related metabolic conditions. Yet the drugs carry steep list prices that make broad employer coverage a significant financial commitment, pushing many human resources and benefits teams to explore alternative strategies rather than open the door wider.
Read more Multistate Lawsuit Expected to Target Paramount-Warner Bros. Deal →
Rather than dropping coverage outright or expanding it, a growing number of employers appear to be threading the needle — maintaining existing benefit structures while finding administrative or policy-based ways to manage utilization and costs. These workarounds may include stricter prior authorization requirements, mandatory step therapy protocols, or limiting coverage to employees who meet specific clinical criteria, all designed to control spending without eliminating the benefit entirely.
The data suggests that the business calculus around GLP-1s remains deeply uncertain for employers. While some research points to long-term cost savings through reduced cardiovascular events and other obesity-related complications, the upfront expense continues to deter broader adoption. Until pricing pressures ease or more compelling cost-benefit evidence emerges, the coverage landscape for GLP-1 obesity treatment is likely to remain largely static across corporate America.
Continue reading at US Top News and Analysis.
